Illumina Raises Revenue Outlook and Forecasts 2026 EPS Following Strong Q3 Performance
Illumina (ILMN) reported a strong third quarter, exceeding previous guidance for revenue, margins, and earnings per share. The company's performance was primarily driven by robust demand in clinical sequencing and increased placements of its NovaSeq X platform. Looking ahead, management has raised its revenue outlook to a range of $4.64 billion to $4.66 billion. Furthermore, the company provided long-term guidance for 2026, forecasting earnings per share (EPS) between $5.40 and $5.45.
Tickers: $ILMN
Topics: clinical sequencing demand earnings report EPS beat revenue beat
Read the full article at Seeking Alpha
Part of the story Pfizer Raises 2026 Revenue Guidance Amid Strong Growth in Acquired Products (18 articles)